Expertise in
27
conditions

Dr. Breelyn A. Wilky

Oncology
Umhc-Sylvester Comprehensive Cancer Center
1475 NW 12th Ave, 
Miami, FL 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
27
conditions
Umhc-Sylvester Comprehensive Cancer Center
1475 NW 12th Ave, 
Miami, FL 

Overview

Breelyn Wilky is an Oncologist practicing medicine in Miami, Florida.

Dr. Wilky is highly rated in 27 conditions, according to our data. Her clinical expertise encompasses Adult Soft Tissue Sarcoma, Alveolar Soft Part Sarcoma, Desmoid Tumor, and Gastrointestinal Stromal Tumor.

She is actively involved in clinical research, co-authoring 90 peer reviewed articles and participating in 21 clinical trials. Dr. Wilky is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in FL

Hospital Affiliations

Uchealth Highlands Ranch Hospital
Poudre Valley Hospital
University Of Colorado Hospital Authority
Uchealth Broomfield Hospital
Longs Peak Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Community Health Options
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Louisiana Healthcare Connections
  • HMO
  • MANAGED MEDICAID PLAN
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Mountain Health
  • OTHER COMMERCIAL
  • POS
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
SelectHealth
  • HMO
  • POS
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

Umhc-Sylvester Comprehensive Cancer Center
1475 NW 12th Ave, Miami, FL 33136
Other Locations
University of Colorado Hospital
1665 Aurora Ct, Aurora, CO 80045

Additional Areas of Focus

Dr. Wilky has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

21 Clinical Trials

A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma
A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma
Enrollment Status: Recruiting
Publish Date: February 25, 2026
Intervention Type: Drug
Study Drugs: Anlotinib, Decarbazine
Study Phase: Phase 3
A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma
A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Procedure, Drug
Study Phase: Phase 2
A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma
A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib-S-Malate, Nivolumab, Paclitaxel
Study Phase: Phase 2
A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T Cells in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T Cells in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Enrollment Status: Active_not_recruiting
Publish Date: August 26, 2026
Intervention Type: Genetic
Study Phase: Phase 2
A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma
A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: July 14, 2026
Intervention Type: Drug
Study Drug: INBRX-109
Study Phase: Phase 2
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)
Enrollment Status: Completed
Publish Date: June 17, 2026
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Doxorubicin, Ifosfamide, Pazopanib
Study Phase: Phase 2/Phase 3
An Open-Label, Phase II Efficacy Trial of Doxorubicin in Combination With Dual Checkpoint Blockade Using Zalifrelimab (AGEN1884) or Botensilimab (AGEN1181) With Balstilimab (AGEN2034) for Advanced or Metastatic Soft Tissue Sarcomas
An Open-Label, Phase II Efficacy Trial of Doxorubicin in Combination With Dual Checkpoint Blockade Using Zalifrelimab (AGEN1884) or Botensilimab (AGEN1181) With Balstilimab (AGEN2034) for Advanced or Metastatic Soft Tissue Sarcomas
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2026
Intervention Type: Drug
Study Drugs: Doxorubicin, AGEN1884 Anti-CTLA-4 Antibody, AGEN2034 Anti-PD-1 Antibody
Study Phase: Phase 2
A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034 (Balstilimab), an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancer
A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034 (Balstilimab), an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 30, 2026
Intervention Type: Drug
Study Phase: Phase 1
A Randomized Phase II Trial of Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma
A Randomized Phase II Trial of Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma
Enrollment Status: Active_not_recruiting
Publish Date: November 12, 2025
Intervention Type: Drug
Study Drugs: Cabozantinib, Nivolumab, Ipilimumab
Study Phase: Phase 2
A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and in Combination With Nivolumab in Adult and Adolescent Patients 12 Years and Older With Advanced Solid Tumors
A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and in Combination With Nivolumab in Adult and Adolescent Patients 12 Years and Older With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Biological
Study Drug: CAB-AXL-ADC
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

90 Total Publications

Precision Oncology in Soft Tissue Sarcomas and Gastrointestinal Stromal Tumors.
Precision Oncology in Soft Tissue Sarcomas and Gastrointestinal Stromal Tumors.
Journal: Hematology/oncology clinics of North America
Published: September 02, 2026
Similar Doctors
Expertise in
58
conditions
Dr. Ricardo J. Komotar
Oncology | Neurosurgery
Expertise in
58
conditions
Dr. Ricardo J. Komotar
Oncology | Neurosurgery
Referral may be required
1295 Northwest 14th Street, 
Miami, FL 
 (0.1 miles away)
305-243-6946
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Ricardo Komotar is an Oncologist and a Neurosurgery provider practicing medicine in Miami, Florida. Dr. Komotar is highly rated in 58 conditions, according to our data. His clinical expertise encompasses Brain Tumor, Meningioma, Glioblastoma, Awake Craniotomy, and Posterior Fossa Decompression. Dr. Komotar is currently accepting new patients.

Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required

Baptist Health Miami Cancer Institute

8900 N Kendall Dr, 
Miami, FL 
 (10.7 miles away)
786-345-7208
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Manmeet Ahluwalia is an Oncologist practicing medicine in Miami, Florida. Dr. Ahluwalia is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Brain Tumor, Glioblastoma, Astrocytoma, and Glioma. Dr. Ahluwalia is currently accepting new patients.

Expertise in
14
conditions
Expertise in
14
conditions
Referral may be required
1425 Northwest 10th Avenue, 
Miami, FL 
 (0.2 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Emanuela Palmerini is an Oncologist practicing medicine in Miami, Florida. Dr. Palmerini is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Adult Soft Tissue Sarcoma, Osteosarcoma, Chondrosarcoma, and Ewing Sarcoma. Dr. Palmerini is currently accepting new patients.

Frequently Asked Questions about Dr. Breelyn A. Wilky

How do I make an appointment with Dr. Breelyn A. Wilky?

You can book an appointment with Dr. Breelyn A. Wilky by calling their office at 305-243-1287. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Breelyn A. Wilky a top-rated expert for Adult Soft Tissue Sarcoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Breelyn A. Wilky is classified as an Elite expert for Adult Soft Tissue Sarcoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Breelyn A. Wilky specialize in?

While Dr. Breelyn A. Wilky is a Oncology, they have specific expertise in Adult Soft Tissue Sarcoma, Alveolar Soft Part Sarcoma, and Desmoid Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Breelyn A. Wilky participate in research or clinical trials?

Yes. Dr. Breelyn A. Wilky has published 90 articles and abstracts on conditions like Adult Soft Tissue Sarcoma. You can view a list of Dr. Breelyn A. Wilky's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Breelyn A. Wilky accept my insurance?

Dr. Breelyn A. Wilky accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 305-243-1287 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wilky's expertise for a condition
ConditionClose
View All 16 Distinguished Conditions
View All 25 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile